Biocytogen Expands Partnership with Merck
Beijing, China and Darmstadt, Germany, August 25, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered into a global licensing agreement with Merck for the…
Read more2022 Popular Mouse Models and Cell Lines
Biocytogen’s advanced genome editing technologies have been leveraged by our own development scientists to create hundreds of animal and cell models used in biomedical research…
Read moreFirst Half of 2022 Publications Highlight
Our off-the-shelf and custom animal and cell models are advancing cutting-edge biomedical research every day. One measure of this impact is how often they appear…
Read moreWebinar: Preclinical Models to Investigate NK Cell-Targeted Immunotherapies
Our webinar “Preclinical Models to Investigate NK Cell-Targeted Immunotherapies" was live on Aug 31, 2022 at 1PM EDT. In this webinar, we Reviewed the mechanisms…
Read more18th International SCBA Symposium
Attend the meeting Talk to us The Society of Chinese Bioscientists in America (SCBA) is a non-profit organization founded by a few prominent and enthusiastic bioscientists…
Read moreBiocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs
Beijing, China and Tokyo, Japan, July 21, 2022 – February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co.,…
Read moreBasic Cardiovascular Sciences Scientific Sessions 2022
Attend the meeting Talk to us at booth 9 The annual BCVS Scientific Sessions is one of largest meetings in the world dedicated to fundamental…
Read moreBiocytogen/Eucure Biopharma Announce First Patient Dosed in Phase II Clinical Trial of YH003 Combination Therapy as a First-Line Treatment for Mucosal Melanoma
Beijing, China, July 12, 2022 -- Biocytogen subsidiary Eucure Biopharma announced that the first patient has been dosed in a phase II clinical trial (No.…
Read moreTumor Models Boston 2022
Attend the meeting Talk to us Meet our expert scientists to learn about our recent advances in preclinical drug evaluation, which includes new humanized animal…
Read moreEACR 2022 Congress
EACR 2022 is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest…
Read more